VIRI – virios therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Virios Therapeutics, Inc. (NASDAQ: VIRI) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.00 price target on the stock.
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study [Yahoo! Finance]
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
Form 8-K Virios Therapeutics, For: Jun 18
Form 8-K Virios Therapeutics, For: Jun 11
Form 424B4 Virios Therapeutics,
Form 8-K Virios Therapeutics, For: May 19
Form 424B4 Virios Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.